{{Rsnum
|rsid=17390445
|Chromosome=4
|position=34892233
|Orientation=plus
|GMAF=0.3508
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 14.2 | 38.9 | 46.9
| HCB | 0.0 | 12.4 | 87.6
| JPT | 0.9 | 8.8 | 90.3
| YRI | 55.1 | 38.8 | 6.1
| ASW | 45.6 | 36.8 | 17.5
| CHB | 0.0 | 12.4 | 87.6
| CHD | 0.0 | 13.2 | 86.8
| GIH | 5.9 | 35.6 | 58.4
| LWK | 45.5 | 50.0 | 4.5
| MEX | 5.3 | 49.1 | 45.6
| MKK | 37.2 | 46.8 | 16.0
| TSI | 15.7 | 46.1 | 38.2
| HapMapRevision=28
}}

One of the only SNPs in a large GWAS study to have statistical significance in terms of helping to predict anti-psychotic drug ([[ziprasidone]] in this case) response by [[schizophrenia]] patients.{{PMID|19721433|OA=1
}}

{{PMID Auto GWAS
|PMID=19721433
|Trait=Treatment response to antipsychotics
|Title=Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics
|RiskAllele=
|Pval=1E-7
|OR=17.00
|ORtxt=[NR] % of variance explained
|OA=1
}}

{{PMID Auto
|PMID=21162693
|Title=Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17390445
|overall_frequency_n=72
|overall_frequency_d=126
|overall_frequency=0.571429
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=59
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}